Short-Course Peptide Allergy Shots for Grass Pollen: Finding the Right Dose
A three-week course of ryegrass peptide injections at 170 μg significantly reduced allergic eye reactions and boosted protective antibodies in grass pollen-allergic adults.
Quick Facts
What This Study Found
A short-course peptide immunotherapy using ryegrass pollen peptides (LPP) significantly reduced allergic eye reactions in grass pollen-allergic adults. The 170 μg dose was the sweet spot: 51.2% of patients improved by at least one concentration step on the conjunctival provocation test (vs. 25.6% on placebo, p=0.023), and 39% became completely non-reactive to the allergen challenge compared to only 18% on placebo.
The treatment also triggered dose-dependent increases in protective IgG4 antibodies — 1.6-fold at 70 μg, 3.1-fold at 170 μg, and 3.9-fold at 370 μg — confirming that the immune system was being reprogrammed to tolerate the allergen. All of this was achieved with just 3-4 weeks of weekly injections, far shorter than conventional allergy immunotherapy.
Key Numbers
n=198 · 3 doses tested: 70, 170, 370 μg · 51.2% improved at 170 μg vs 25.6% placebo (p=0.023) · 39% became non-reactive vs 18% placebo · IgG4 increased 3.1-fold at 170 μg · 3-4 weeks treatment duration
How They Did This
This was a prospective, double-blind, placebo-controlled phase IIb dose-finding trial. 198 grass pollen-allergic adults were randomized to receive placebo or one of three cumulative doses (70, 170, or 370 μg) of Lolium perenne peptides via weekly subcutaneous injections over 2-4 weeks. Efficacy was measured using conjunctival provocation tests (dropping allergen into the eye and measuring the reaction) at baseline and after treatment. Blood samples were taken to measure changes in allergen-specific antibodies.
Why This Research Matters
Traditional allergy immunotherapy (allergy shots) typically requires months to years of treatment. This peptide-based approach achieved significant clinical improvement and immune changes in just three weeks of injections. If confirmed in larger trials, this could dramatically reduce the burden of allergy treatment for the millions of people who suffer from grass pollen allergies each year.
The Bigger Picture
Peptide immunotherapy represents a new generation of allergy treatments that aim to deliver the benefits of traditional allergy shots in a fraction of the time. By using hydrolyzed peptide fragments rather than whole allergen extracts, these formulations may also carry a lower risk of triggering allergic reactions during treatment. This dose-finding study was a critical step in the development pipeline for gpASIT+, bringing short-course allergy immunotherapy closer to clinical reality.
What This Study Doesn't Tell Us
As a phase IIb dose-finding study, the sample size (198 total, ~50 per arm) is moderate and primarily designed to identify the optimal dose, not to provide definitive proof of efficacy. The primary outcome was a laboratory provocation test rather than real-world symptom scores during pollen season. Longer follow-up would be needed to assess durability of the effect. The abstract's description of antibody results appears partially truncated.
Questions This Raises
- ?Does this short-course treatment provide lasting protection through an entire pollen season, or do effects fade quickly?
- ?How does this peptide immunotherapy compare to sublingual (under-the-tongue) allergy tablets in terms of convenience and efficacy?
- ?Could combining this approach with other immunomodulators enhance the response rate beyond 51%?
Trust & Context
- Key Stat:
- 39% became non-reactive After just 3 weeks of peptide injections at the optimal dose, 39% of patients no longer reacted to direct allergen exposure, compared to 18% on placebo
- Evidence Grade:
- This is a well-designed randomized, double-blind, placebo-controlled phase IIb trial — the gold standard design for dose-finding studies. However, with 198 participants split across four arms and a laboratory-based primary outcome, the evidence is moderate rather than strong. Larger phase III trials with real-world symptom outcomes would provide stronger evidence.
- Study Age:
- Published in 2018 in Allergy, a leading immunology journal. The study is relatively recent and represents ongoing development in the peptide immunotherapy field.
- Original Title:
- A randomized, double-blind, placebo-controlled, dose-finding trial with Lolium perenne peptide immunotherapy.
- Published In:
- Allergy, 73(4), 896-904 (2018)
- Authors:
- Mösges, R, Kasche, E M, Raskopf, E, Singh, J, Sohlich, L, Astvatsatourov, A, Shah-Hosseini, K, Pirotton, S, Haazen, L, Durham, S R, Legon, T, Zadoyan, G, Shamji, M H
- Database ID:
- RPEP-03818
Evidence Hierarchy
Frequently Asked Questions
How is peptide immunotherapy different from regular allergy shots?
Traditional allergy shots use whole allergen extracts and require months to years of gradually increasing doses. Peptide immunotherapy uses smaller, broken-down fragments of the allergen protein, which may retrain the immune system faster with fewer side effects. This study achieved results in just 3 weeks of weekly injections.
Is this treatment available now?
This formulation (gpASIT+) was in clinical development as of 2018. It is not yet a widely approved product. Patients with grass pollen allergies should discuss currently available immunotherapy options — including traditional allergy shots and sublingual tablets — with their allergist.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-03818APA
Mösges, R; Kasche, E M; Raskopf, E; Singh, J; Sohlich, L; Astvatsatourov, A; Shah-Hosseini, K; Pirotton, S; Haazen, L; Durham, S R; Legon, T; Zadoyan, G; Shamji, M H. (2018). A randomized, double-blind, placebo-controlled, dose-finding trial with Lolium perenne peptide immunotherapy.. Allergy, 73(4), 896-904. https://doi.org/10.1111/all.13358
MLA
Mösges, R, et al. "A randomized, double-blind, placebo-controlled, dose-finding trial with Lolium perenne peptide immunotherapy.." Allergy, 2018. https://doi.org/10.1111/all.13358
RethinkPeptides
RethinkPeptides Research Database. "A randomized, double-blind, placebo-controlled, dose-finding..." RPEP-03818. Retrieved from https://rethinkpeptides.com/research/mosges-2018-a-randomized-doubleblind-placebocontrolled
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.